Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum

European Journal of Heart Failure

Volumn 20, Issue 8, 2018, Pages 1230-1239

  Lund, Lars H ^a   Claggett, Brian ^b   Liu, Jiankang ^b   Lam, Carolyn S ^c   Jhund, Pardeep S ^d   Rosano, Giuseppe M ^e   Swedberg, Karl ^f   Yusuf, Salim ^g   Granger, Christopher B ^h   Pfeffer, Marc A ^b   McMurray, John J V ^d   Solomon, Scott D ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g HAMILTON HEALTH SCIENCES   (Canada)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin receptor blocker; Candesartan; Heart failure; Mid range ejection fraction; Outcomes; Preserved ejection fraction; Randomized controlled trial

Indexed keywords

CANDESARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH MID RANGE EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EPIDEMIOLOGY; EUROPE; HEART STROKE VOLUME; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; CAUSE OF DEATH; EUROPE; FEMALE; HEART FAILURE; HUMANS; MALE; PROGNOSIS; REGISTRIES; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TETRAZOLES; TREATMENT OUTCOME; UNITED STATES;

EID: 85041927742     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1149     Document Type: Article

References (26)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975
2. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014;16:1049–1055
3. Vedin O, Lam CS, Koh AS, Benson L, Teng TH, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail 2017;10:e003875
4. Lofman I, Szummer K, Dahlstrom U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 2017;19:1606–1614
5. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585
6. Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017;5:565–574
7. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H; CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study. Eur J Heart Fail 2017;19:1258–1269
8. Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017;19:1586–1596
9. Koh AS, Tay WT, Teng TH, Vedin O, Benson L, Dahlstrom U, Savarese G, Lam CS, Lund LH. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017;19:1624–1634
10. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail 2017;19:1597–1605
11. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738–3744
12. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781
13. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766
14. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. J Card Fail 1999;5:276–282
15. Mele D, Nardozza M, Ferrari R. Left ventricular ejection fraction and heart failure: an indissoluble marriage? Eur J Heart Fail 2018;20:427–430
16. Lupon J, Diez-Lopez C, de Antonio M, Domingo M, Zamora E, Moliner P, Gonzalez B, Santesmases J, Troya MI, Bayes-Genis A. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 2017;19:1615–1623
17. Nauta JF, Hummel YM, canMelle JP, van der Meer P, Lam CS, Ponikowski P, Voors AA. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail 2017;19:1569–1573
18. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL study. JACC Cardiovasc Imaging 2015;8:656–665
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270
20. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768–777
21. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011;123:2006–2014
22. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–271
23. Lam CS, Lund LH. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart 2016;102:257–259
24. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750–1757
25. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail 2016;9:e002744
26. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455–462